Research and Markets: Tregalizumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/rjr4qx/tregalizumab) has announced the addition of the "Tregalizumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" report to their offering.

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023.

The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Tregalizumab, also known as BT-061, is a humanized mAb against the CD4 receptor. It works specifically on the immunoglobulin G (IgG)-like C2 type 1 domain of the CD4 receptor in Treg cells, inducing downstream phosphorylation events, leading to the activation of this important regulatory cell. The activation of Treg cells thus reduces the damaging effects of cytokines and T effector cells in active RA.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.2 Symptoms

3.3 Prognosis

3.4 Quality of Life

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.1.1 Diagnosis

4.1.2 Treatment Guidelines

4.1.3 Leading Prescribed Drugs for the Treatment of RA

4.1.4 Clinical Practice

5 Competitive Assessment

6 Unmet Need and Opportunity

6.1 Overview

6.2 Development of Cost-Effective Therapies

6.3 Biomarkers to Predict Responsiveness to Therapy

6.4 Early Diagnosis of RA

6.5 Personalized Treatment Approach

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Clinical Development

8 Tregalizumab

9 Appendix

For more information visit http://www.researchandmarkets.com/research/rjr4qx/tregalizumab

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders